Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be willing to use 2 methods of effective contraception~* Must have venous access~* Must be willing to forego participation in other clinical trials for SLE.~Exclusion Criteria:~* Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product~* Major surgery within 8 weeks before signing informed consent form (ICF)~* Elective major surgery planned during the study period~* Concomitant Medications within the last 12 weeks: Azathioprine \> 200 mg/day, Mycophenolate mofetil/mycophenolic acid \> 2.0 g/day, oral, subcutaneous, or intramuscular methotrexate \> 25 mg/week~* A live or attenuated vaccine within 4 weeks of signing the ICF~* Bacillus of Calmette and Guérin (BCG) vaccine within 1 year of ICF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Anifrolumab (Type: EXPERIMENTAL): Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.

Based on this trial design, predict the completion outcome and termination type (if applicable).